Gregory Renza
Stock Analyst at Truist Financial
(4.86)
# 392
Out of 5,189 analysts
855
Total ratings
51.7%
Success rate
17%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Reiterated: Buy | $100 | $79.47 | +25.83% | 24 | Nov 17, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $11 → $8 | $0.7538 | +961.29% | 22 | Nov 10, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $37 → $35 | $27.60 | +26.81% | 47 | Nov 6, 2026 | |
| GMAB Genmab | Reiterated: Buy | $67 | $50.60 | +32.41% | 10 | Nov 6, 2026 | |
| MNKD MannKind | Reiterated: Buy | $5 | $3.85 | +29.87% | 42 | Nov 6, 2026 | |
| ONC BeOne Medicines AG | Reiterated: Buy | $420 → $448 | $390.94 | +14.60% | 20 | Nov 6, 2026 | |
| AMGN Amgen | Reiterated: Hold | $380 → $398 | $435.64 | -8.64% | 45 | Nov 4, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $57 | $25.56 | +123.00% | 35 | Nov 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $780 → $982 | $920.69 | +6.66% | 16 | Nov 2, 2026 | |
| EXEL Exelixis | Reiterated: Hold | $54 → $60 | $64.63 | -7.16% | 38 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $158 → $181 | $166.43 | +8.75% | 19 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $35 | $26.14 | +33.89% | 9 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $40 | $33.26 | +20.26% | 36 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $240 → $241 | $161.20 | +49.50% | 11 | Oct 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $33 | $12.85 | +156.81% | 28 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $286 | $230.26 | +24.21% | 45 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $85 | $24.77 | +243.16% | 4 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $155 → $151 | $73.20 | +106.28% | 13 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.80 | - | 29 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.96 | - | 37 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.97 | - | 5 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.69 | - | 18 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $2.90 | +141.38% | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $17.11 | n/a | 57 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.28 | n/a | 24 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $1.76 | n/a | 36 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $2.74 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $6.33 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $8.69 | n/a | 8 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $3.82 | n/a | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $13 | $5.27 | n/a | 14 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 | $38.00 | n/a | 26 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,160 → $180 | $6.76 | n/a | 11 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20.41 | $1.62 | n/a | 23 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $80 | $0.229 | n/a | 18 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $15 | $0.000001 | n/a | 14 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $348 | $249.59 | n/a | 1 | Sep 8, 2015 |
CG Oncology
Nov 17, 2026
Reiterated: Buy
Price Target: $100
Current: $79.47
Upside: +25.83%
Perspective Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $11 → $8
Current: $0.7538
Upside: +961.29%
Agios Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $37 → $35
Current: $27.60
Upside: +26.81%
Genmab
Nov 6, 2026
Reiterated: Buy
Price Target: $67
Current: $50.60
Upside: +32.41%
MannKind
Nov 6, 2026
Reiterated: Buy
Price Target: $5
Current: $3.85
Upside: +29.87%
BeOne Medicines AG
Nov 6, 2026
Reiterated: Buy
Price Target: $420 → $448
Current: $390.94
Upside: +14.60%
Amgen
Nov 4, 2026
Reiterated: Hold
Price Target: $380 → $398
Current: $435.64
Upside: -8.64%
IDEAYA Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $57
Current: $25.56
Upside: +123.00%
Regeneron Pharmaceuticals
Nov 2, 2026
Reiterated: Buy
Price Target: $780 → $982
Current: $920.69
Upside: +6.66%
Exelixis
Oct 30, 2026
Reiterated: Hold
Price Target: $54 → $60
Current: $64.63
Upside: -7.16%
Oct 30, 2026
Reiterated: Buy
Price Target: $158 → $181
Current: $166.43
Upside: +8.75%
Oct 29, 2026
Reiterated: Buy
Price Target: $34 → $35
Current: $26.14
Upside: +33.89%
Oct 27, 2026
Reiterated: Buy
Price Target: $29 → $40
Current: $33.26
Upside: +20.26%
Oct 19, 2026
Reiterated: Buy
Price Target: $240 → $241
Current: $161.20
Upside: +49.50%
Oct 13, 2026
Reiterated: Buy
Price Target: $34 → $33
Current: $12.85
Upside: +156.81%
Oct 7, 2026
Reiterated: Buy
Price Target: $286
Current: $230.26
Upside: +24.21%
Oct 7, 2026
Reiterated: Buy
Price Target: $87 → $85
Current: $24.77
Upside: +243.16%
Sep 22, 2026
Reiterated: Buy
Price Target: $155 → $151
Current: $73.20
Upside: +106.28%
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.80
Upside: -
Sep 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.96
Upside: -
Aug 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.97
Upside: -
Aug 18, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.69
Upside: -
Jul 31, 2026
Reiterated: Hold
Price Target: $7
Current: $2.90
Upside: +141.38%
May 19, 2025
Reiterated: Buy
Price Target: $26
Current: $17.11
Upside: n/a
May 14, 2025
Reiterated: Buy
Price Target: $8
Current: $1.28
Upside: n/a
May 13, 2025
Reiterated: Hold
Price Target: $5
Current: $1.76
Upside: n/a
May 13, 2025
Reiterated: Hold
Price Target: $20
Current: $2.74
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: $16
Current: $6.33
Upside: n/a
May 12, 2025
Reiterated: Buy
Price Target: $48 → $46
Current: $8.69
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $16
Current: $3.82
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $12 → $13
Current: $5.27
Upside: n/a
May 6, 2025
Reiterated: Hold
Price Target: $38
Current: $38.00
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: $2,160 → $180
Current: $6.76
Upside: n/a
May 15, 2023
Reiterated: Hold
Price Target: $20.41
Current: $1.62
Upside: n/a
Mar 16, 2022
Reiterated: Hold
Price Target: $5 → $80
Current: $0.229
Upside: n/a
Nov 12, 2021
Reiterated: Hold
Price Target: $1 → $15
Current: $0.000001
Upside: n/a
Sep 8, 2015
Rated: Buy
Price Target: $348
Current: $249.59
Upside: n/a